Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2021

Open Access 01-12-2021 | Correction

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

Authors: Sarah B. Reusing, Dan A. Vallera, Angela R. Manser, Titus Watrin, Sanil Bhatia, Martin Felices, Jeffrey S. Miller, Markus Uhrberg, Florian Babor

Published in: Cancer Immunology, Immunotherapy | Issue 12/2021

Login to get access

Excerpt

The original version of this article unfortunately contained a mistake. Author name Titus Watrin was incorrectly written as Titus Vatrin. …
Metadata
Title
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
Authors
Sarah B. Reusing
Dan A. Vallera
Angela R. Manser
Titus Watrin
Sanil Bhatia
Martin Felices
Jeffrey S. Miller
Markus Uhrberg
Florian Babor
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 12/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-021-03040-0

Other articles of this Issue 12/2021

Cancer Immunology, Immunotherapy 12/2021 Go to the issue

Research Report

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

Original Article

Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice

Review

Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Research Report

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells

Original Article

Immune infiltrate diversity confers a good prognosis in follicular lymphoma

Original Article

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits